Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Fiche publication
Date publication
avril 2011
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles
Tous les auteurs :
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L
Lien Pubmed
Résumé
Estrogen receptor-positive (ER+) and -negative (ER) breast cancers are molecularly distinct diseases. We hypothesized that p53 mutations may lead to different transcriptional changes and carry different prognostic value in these two different types of cancers.
Mots clés
Adult, Aged, Aged, 80 and over, Breast Neoplasms, drug therapy, Female, Gene Expression Profiling, statistics & numerical data, Humans, Middle Aged, Multivariate Analysis, Mutation, Oligonucleotide Array Sequence Analysis, statistics & numerical data, Predictive Value of Tests, Prognosis, Receptors, Estrogen, genetics, Survival Analysis, Tumor Suppressor Protein p53, genetics
Référence
Clin. Cancer Res.. 2011 Apr;17(8):2591-601